ACP Policy Calls for Increased Efforts in Women's Health Issues
The American College of Physicians have published a position paper in Annals of Internal Medicine calling for an examination of the challenges facing women in the U.S.
News
Cancer Risk Raised in Psoriatic Arthritis
Patients with psoriatic arthritis (PsA) were at increased risks for malignancy, and possibly more so if they were treated with conventional disease-modifying antirheumatic drugs (DMARDs), a meta-analysis found.
In nine cohort studies that included more than 43,000 PsA patients, the pooled relative risk for overall malignancy was 1.29 (95% CI 1.04-1.60) compared with the general population, according to Yunyun Fei, MD, and colleagues from Peking Union Medical College in Beijing.
Restless Sleep and Inactivity Intertwined in OA
Adults with osteoarthritis (OA) of the knee who frequently experienced restless sleep were less likely to engage in potentially beneficial moderate-to-vigorous physical activity, analysis of data from the Osteoarthritis Initiative found.
The RheumNow Week in Review – Methotrexate CIRT Study (5.25.18)
Dr. Jack Cush reviews this past week's news from RheumNow.com - the risk of Cutaneous and Systemic LE, increasing flu vaccination, higher risk of VTE, MPO predictions, new drug for GIOP and CIRT - MTX in cardiovascular risk patients.
Measures of Opioid Misuse Predict Future Opioid Overdose and Death
The current issue of Annals of Internal Medicine examines patterns of potential opioid misuse that are associated with subsequent adverse outcomes nationally.
MPO Antibodies Predict Relapses in MPO-ANCA-Associated Vasculitis
A study of MPO-ANCA positive patients followed serially over 2 years shows that reappearance of MPO‐ANCA may predict relapse in patients with MPO‐ANCA positive AAV and that routine MPO‐ANCA monitoring is warranted.
FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis
Amgen announced that the U.S.
ACR Leaders Lobby Capitol Hill for Help on Rising Costs and Access Barriers in Arthritis Care
Rheumatologists and rheumatology health professionals convened on Capitol Hill this week to urge legislative action on pressing policy issues affecting rheumatology care during the American College of Rheumatology’s Advocacy Leadership Conference, held May 16 -17, 2018 in Washington, D.C.
Autoinflammatory Syndromes Show Dramatic Response to Canakinumab
The New England Journal of Medicine reports that the anti-interleukin (IL)-1β monoclonal antibody canakinumab (Ilaris) was effective in the treatment of three distinct autoinflammatory recurrent fever syndromes (FMF, TRAPS, HIDS) with responses that were far superior to what was see
The RheumNow Week in Review – Modifiable Behavior (5.18.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis, and modifiable behaviors that influence outcomes.
Treat-to-Target a Bust with Rheumatologists
Treat-to-target strategy is widely advocated as an important means of optimizing treatment responses in patients with rheumatoid arthritis. Even though T2T is encouraged by most guidelines, a current report shows that US Rheumatologists fail to implement T2T in their daily practice.
Trends in Psoriatic Arthritis Treatment 2004-2015
Lee and colleagues from Brigham and Women's Hospital have analyzed the last decade of disease‐modifying antirheumatic drugs (DMARDs) use in patients with psoriatic arthritis (PsA) and found nearly 40% were treated with a bDMARD, along with a decreasing trend in complete DMARD discontinuations.
